Float Short %

38.26

Margin Of Safety %

Put/Call OI Ratio

2.37

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

16.86

Target Price

Analyst Recom

Performance Q

8.01

Relative Volume

0.53

Beta

-0.15

Ticker: KALV

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-10	KALV	10.9	0.91	0.00	14754
2025-11-11	KALV	11.48	0.85	40.91	15311
2025-11-12	KALV	13.36	1.45	0.01	20351
2025-11-13	KALV	13.11	1.45	0.00	20350
2025-11-14	KALV	13.62	1.45	0.00	20349
2025-11-17	KALV	14.85	1.45	0.00	20357
2025-11-18	KALV	14.25	1.29	0.36	21369
2025-11-19	KALV	13.69	1.29	0.00	21384
2025-11-20	KALV	13.02	1.29	0.01	21397
2025-11-21	KALV	13.11	1.04	0.00	23712
2025-11-24	KALV	13.38	1.27	0.28	20992
2025-11-25	KALV	13.26	1.27	5.38	21010
2025-11-26	KALV	14.1	1.27	244.59	21061
2025-12-01	KALV	13.9	2.36	0.10	31078
2025-12-02	KALV	13.53	2.22	0.77	31758
2025-12-03	KALV	14.64	2.22	0.14	31761
2025-12-04	KALV	16.4	2.32	0.03	31654
2025-12-05	KALV	16.46	2.28	0.00	31816
2025-12-08	KALV	16.88	2.37	0.16	31446
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-10	KALV	10.89	-16.5	-	-3.79
2025-11-11	KALV	11.47	-16.5	-	-3.79
2025-11-12	KALV	13.36	-16.5	-	-3.79
2025-11-13	KALV	13.10	-16.5	-	-3.79
2025-11-14	KALV	13.62	-19.8	-	-4.06
2025-11-17	KALV	14.84	-19.8	-	-4.06
2025-11-18	KALV	14.26	-19.8	-	-4.06
2025-11-19	KALV	13.71	-19.8	-	-4.06
2025-11-20	KALV	13.02	-19.8	-	-4.06
2025-11-21	KALV	13.10	-	-	-
2025-11-24	KALV	13.38	-	-	-
2025-11-25	KALV	13.28	-	-	-
2025-11-26	KALV	14.11	-	-	-
2025-12-01	KALV	13.91	-	-	-
2025-12-02	KALV	13.52	-	-	-
2025-12-03	KALV	14.66	-	-	-
2025-12-04	KALV	16.41	-	-	-
2025-12-05	KALV	16.43	-	-	-
2025-12-08	KALV	16.86	-	-	-
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-10	KALV	-1.09	0.50	38.42
2025-11-11	KALV	-1.08	0.50	38.42
2025-11-12	KALV	-1.08	0.50	35.32
2025-11-13	KALV	-1.11	0.50	35.31
2025-11-14	KALV	-1.11	0.50	35.05
2025-11-17	KALV	-1.13	5.63	35.16
2025-11-18	KALV	-1.12	5.63	35.16
2025-11-19	KALV	-1.20	5.63	35.16
2025-11-20	KALV	-1.20	5.63	35.16
2025-11-21	KALV	-1.13	5.63	35.16
2025-11-24	KALV	-1.01	5.22	35.17
2025-11-25	KALV	-1.01	5.22	35.17
2025-11-26	KALV	-1.01	5.22	38.14
2025-12-01	KALV	-1.17	4.32	38.23
2025-12-02	KALV	-1.17	4.32	38.26
2025-12-03	KALV	-1.16	4.32	38.26
2025-12-04	KALV	-1.19	4.32	38.26
2025-12-05	KALV	-1.19	4.32	38.26
2025-12-08	KALV	-1.19	5.25	38.26
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.76

Avg. EPS Est. Next Quarter

-0.61

Insider Transactions

-1.19

Institutional Transactions

5.25

Beta

-0.15

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

62.5

Max Drawdown 5-Year %

-90.1

Target Price

P/E

Forward P/E

18.53

PEG

P/S

595.95

P/B

50.13

P/Free Cash Flow

EPS

-4

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

-2.79

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-14242.57

Relative Volume

0.53

Return on Equity vs Sector %

-524.8

Return on Equity vs Industry %

-509.9

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

KalVista Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 270

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. KalVista Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

stock quote shares KALV – KalVista Pharmaceuticals Inc Stock Price stock today

news today KALV – KalVista Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch KALV – KalVista Pharmaceuticals Inc yahoo finance google finance

stock history KALV – KalVista Pharmaceuticals Inc invest stock market

stock prices KALV premarket after hours

ticker KALV fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: KALV

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y